110 related articles for article (PubMed ID: 11981366)
1. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study.
Kirstein LM; Greenblatt RM; Anastos K; Levine A; French AL; Minkoff H; Silver S; Gange SJ;
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):495-503. PubMed ID: 11981366
[TBL] [Abstract][Full Text] [Related]
2. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
3. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
[TBL] [Abstract][Full Text] [Related]
4. Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.
Slama L; Li X; Brown T; Jacobson LP; Pialoux G; Macatangay B; Bolan RK; Phair J; Palella FJ;
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):57-64. PubMed ID: 24419062
[TBL] [Abstract][Full Text] [Related]
5. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study.
Berhane K; Karim R; Cohen MH; Masri-Lavine L; Young M; Anastos K; Augenbraun M; Watts DH; Levine AM
J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1245-52. PubMed ID: 15385731
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.
Silverberg MJ; Gore ME; French AL; Gandhi M; Glesby MJ; Kovacs A; Wilson TE; Young MA; Gange SJ
Clin Infect Dis; 2004 Sep; 39(5):717-24. PubMed ID: 15356788
[TBL] [Abstract][Full Text] [Related]
7. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
Sterling TR; Chaisson RE; Moore RD
AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
10. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
Kaufmann GR; Khanna N; Weber R; Perrin L; Furrer H; Cavassini M; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Antivir Ther; 2004 Apr; 9(2):263-74. PubMed ID: 15134189
[TBL] [Abstract][Full Text] [Related]
11. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
12. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
13. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
[TBL] [Abstract][Full Text] [Related]
14. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
[TBL] [Abstract][Full Text] [Related]
15. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
Vaamonde CM; Hoover DR; Anastos K; Tan T; Shi Q; Gao W; Kovacs A; Cohen M; DeHovitz J; Glesby MJ
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):222-31. PubMed ID: 16545008
[TBL] [Abstract][Full Text] [Related]
18. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
[TBL] [Abstract][Full Text] [Related]
20. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
